↓ Skip to main content
Embed badge What is this page?

Eleven years of experience with bisphosphonate plus alfacalcidol treatment in a man with osteogenesis imperfecta type I

Overview of attention for article published in Therapeutics and Clinical Risk Management, December 2012
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter
facebook
2 Facebook pages

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
18 Mendeley

What is this page?

Summary Twitter Facebook Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Eleven years of experience with bisphosphonate plus alfacalcidol treatment in a man with osteogenesis imperfecta type I
Published in
Therapeutics and Clinical Risk Management, December 2012
DOI 10.2147/tcrm.s38404
Pubmed ID
23293527
Authors

Jun Iwamoto, Hideo Matsumoto, Mitsuyoshi Uzawa, Yoshihiro Sato

Abstract

We report the 11-year follow-up of a man with osteogenesis imperfecta type I who was treated with bisphosphonates and alfacalcidol. A 36-year-old Japanese man with osteogenesis imperfecta type I who had frequently experienced painful fragility fractures consulted our clinic because of chronic back pain. The patient had multiple morphometric vertebral fractures and a low bone mineral density (BMD) at the lumbar spine. The patient was treated with cyclical etidronate 200 mg, for 2 weeks every 3 months, plus alfacalcidol 1 μg daily, for 2 years; and alendronate 5 mg daily or 35 mg weekly, plus alfacalcidol 1 μg daily for 9 years. After 11 years of treatment, BMD at the lumbar spine increased by 6.4%, following a 20.3% reduction in serum alkaline phosphatase. Serum calcium, phosphorus, and intact parathyroid hormone levels remained within the normal ranges. Three clinical fractures occurred at two ribs and the metacarpus, and two morphometric vertebral fractures occurred at the thoracic spine during the 11-year treatment period, but the patient experienced no adverse effects. Thus, the present case report shows the long-term outcome and safety of bisphosphonate plus alfacalcidol treatment in a man with osteogenesis imperfecta type I.

View on publisher site

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 18 100%

Demographic breakdown

Readers by professional status Count As %
Other 2 11%
Student > Doctoral Student 2 11%
Student > Master 2 11%
Student > Postgraduate 2 11%
Student > Ph. D. Student 1 6%
Other 3 17%
Unknown 6 33%
Readers by discipline Count As %
Medicine and Dentistry 8 44%
Unspecified 1 6%
Neuroscience 1 6%
Decision Sciences 1 6%
Unknown 7 39%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 March 2013.
All research outputs
#15,260,208
of 22,691,736 outputs
Outputs from Therapeutics and Clinical Risk Management
#864
of 1,259 outputs
Outputs of similar age
#178,969
of 277,193 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#4
of 7 outputs
Altmetric has tracked 22,691,736 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,259 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one is in the 24th percentile – i.e., 24% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,193 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.

This page is provided by Altmetric.